The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

Around half of the pharmaceutical products launched in the USA in 2023 underperformed, and 39% overperformed, according to ...

PrognomiQ has raised $34 million in a series D round led by Seer, boosting its total funding to over $135 million. The funds ...

USA-based Acadia Pharmaceuticals has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease ...

Some of the UK’s leading academics and industry professionals have welcomed Chancellor Rachel Reeves’ £520 million ($669 ...

India’s Sun Pharma has been blocked in its efforts to launch its JAK inhibitor Leqselvi (deuruxolitinib) in the USA.

The ROS1 inhibitor market for NSCLC, valued at around $290 million in 2023 across the USA, Europe, and Japan, is set for growth with new-generation therapies targeting resistance mutations.

Teva Pharmaceutical Industries’ shares were up 4% at 7,323 shekels today reported results for the quarter ended September 30, 2024.

Syndax Pharmaceuticals has entered a $350 million royalty agreement with Royalty Pharma, granting a 13.8% royalty on US sales of Niktimvo for chronic graft-versus-host disease, ending once Royalty ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) issued final guidance recommending ...

French drugmaker Sanofi has revealed the results from the Phase III LUNA 3 trial of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor, in persistent or chronic immune thrombocytopenia (ITP ...